Sugi Predict

Sugi Predict / Compounds / SCHEMBL564964

SCHEMBL564964

SCHEMBL564964

CC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 9/20 0.86
▸ CYP3A4 P08684 5/20 0.86
▸ PGR P06401 4/20 0.86
▸ USP2 O75604 3/20 0.86
▸ LMNA P02545 3/20 0.86
▸ NR1I2 O75469 2/20 0.86
▸ MAPT P10636 2/20 0.86
▸ CYP2C9 P11712 2/20 0.86
▸ MLNR O43193 1/20 0.86
▸ ABCB11 O95342 1/20 0.86
▸ CYP3A5 P20815 1/20 0.86
▸ PPARG P37231 1/20 0.86
▸ SMN1; SMN2 Q16637 1/20 0.86
▸ NPSR1 Q6W5P4 1/20 0.86
▸ CYP2D6 P10635 1/20 0.86
▸ MMP1 P03956 6/20 0.72
▸ ADORA3 P0DMS8 1/20 0.72
▸ DRD2 P14416 1/20 0.72
▸ OPRD1 P41143 1/20 0.72
▸ MEN1 O00255 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11582111 1.00 NR3C1 (0.86) NR3C1CYP3A4PGRUSP2LMNA
SCHEMBL11580982 1.00 NR3C1 (0.86) NR3C1CYP3A4PGRUSP2LMNA
Clobetasol Propionate SCHEMBL11052078 0.93 PGR (1.00) NR3C1CYP3A4PGRUSP2LMNA
Clobetasol Propionate SCHEMBL10865006 0.93 PGR (1.00) NR3C1CYP3A4PGRUSP2LMNA
Clobetasol Propionate SCHEMBL5577908 0.93 PGR (1.00) NR3C1CYP3A4PGRUSP2LMNA
SCHEMBL9159208 0.93 NR3C1 (0.85) NR3C1CYP3A4PGRUSP2LMNA
Clobetasol Propionate SCHEMBL445257 0.93 PGR (1.00) NR3C1CYP3A4PGRUSP2LMNA
SCHEMBL10599326 0.93 NR3C1 (0.82) NR3C1CYP3A4PGRUSP2LMNA
Clobetasol Propionate SCHEMBL5577907 0.93 PGR (1.00) NR3C1CYP3A4PGRUSP2LMNA
Clobetasol Propionate SCHEMBL3997 0.93 PGR (1.00) NR3C1CYP3A4PGRUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114942281-A Method for identifying clobetasol acetate in cosmetics 上海市食品药品检验研究院 2022-08-26 — — CN claimed
CN-110123830-A Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare 阿尔尼拉姆医药品有限公司 2019-08-16 — — CN claimed
CN-103370054-A Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes ALNYLAM PHARMACEUTICALS INC 2013-10-23 — — CN claimed
WO-2012064824-A1 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES ALNYLAM PHARMACEUTICALS, INC. (US) 2012-05-18 — — WO claimed
CN-118252869-A Formulation comprising omega-3 fatty acid salts and gum resin extract from boswellia species 赢创运营有限公司 2024-06-28 — — CN disclosed
CN-118043056-A Liquid skin external composition 狮王株式会社 2024-05-14 — — CN disclosed
CN-114942281-A Method for identifying clobetasol acetate in cosmetics 上海市食品药品检验研究院 2022-08-26 — — CN disclosed
CN-114942281-A Method for identifying clobetasol acetate in cosmetics 上海市食品药品检验研究院 2022-08-26 — — CN disclosed
CN-114942281-A Method for identifying clobetasol acetate in cosmetics 上海市食品药品检验研究院 2022-08-26 — — CN disclosed
CN-104922699-B Lipid formulated compositions and methods for inhibiting the expression of Eg5 and VEGF genes 阿尔尼拉姆医药品有限公司 2020-07-24 — — CN disclosed
US-10550386-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) ALNYLAM PHARMACEUTICALS, INC. (US) 2020-02-04 — — US disclosed
CN-105744983-B Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents 纳米医学系统公司 2019-12-27 — — CN disclosed
WO-2010105209-A1 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES ALNYLAM PHARMACEUTICALS, INC. (US) 2010-09-16 — — WO disclosed
WO-2010039548-A2 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS, INC. (US) 2010-04-08 — — WO disclosed
US-20100087508-A1 Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes ALNYLAM PHARMACEUTICALS, INC. 2010-04-08 — — US disclosed
WO-2010028079-A2 SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2010-03-11 — — WO disclosed
WO-2009111658-A2 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES ALNYLAM PHARMACEUTICALS, INC. (US) 2009-09-11 — — WO disclosed
WO-2009091915-A1 COMBINATION THERAPY COMPRISING ACTINIDIA AND STEROIDS AND USES THEREOF EFFICAS, INC. (US) 2009-07-23 — — WO disclosed
US-20080175888-A1 Combination Therapy Comprising Actinidia and Steroids and Uses Thereof EFFICAS, INC. 2008-07-24 — — US disclosed
US-4113680-A Method for preparing 17 α-ester-21-halo pregnanes TAISHO PHARMACEUTICAL CO., LTD. (JP) 1978-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550386-B2 Monomers and oligonucleotides comprising cycloaddition adduct(s) FANCI, PCNA, DNMT1 NR3C1 237/4885CYP3A4 1668/4885PGR 3184/4885
US-20100087508-A1 Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes GEMIN5, KLF5, EDF1 NR3C1 3412/4885CYP3A4 4827/4885PGR 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback